Multicenter, Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Efficacy and Safety of XC8 in Patients With the Eosinophilic Phenotype of Bronchial Asthma
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 70
- 试验地点
- 18
- 主要终点
- Rate of achieving the minimal clinically significant absolute change in FEV1 (+200 mL)
研究概览
简要总结
A multicenter, double-blind, randomized, pilot study in parallel groups to assess the efficacy and safety of XC8 at a dose of 100 mg versus placebo over a 12-week treatment period in non-smoking patients with a confirmed bronchial asthma (BA) and the eosinophil blood level 2 times within 1 week interval of ≥ 300 cells/μl.
Study design was developed by Chemlmmune Therapeutics LLC, Russia in cooperation with Eurrus Biotech GmbH, Austria.
详细描述
The study consists of 3 periods: screening (2 weeks), treatment period (12 weeks) and follow-up (2 weeks). All eligible patients are randomized into one of two treatment groups in a ratio of 1:1. During the study patients will continue to receive stable doses of inhaled corticosteroids (ICS) with or without the long-acting β2-agonists; when required, patients will receive short-acting β2-agonists.The randomized patients will be stratified by the site, baseline forced expiratory volume (FEV1) in the range of 55 to 70% and 71% to 85%, and therapy of BA (inhaled corticosteroids (ICS) with or without long-acting β2 agonists).
The Study drug is produced by Hennig Arzneimittel GmbH und Co., Germany.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
盲法说明
For blinding purposes the Placebo was made with the corresponding labelling of the study drug.
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed Informed Consent Form;
- •Male and female non-smokers of 18 to 65 years of age (inclusive);
- •The diagnosis of asthma not earlier than 12 months prior to screening;
- •Steps 2 and 3 according to Global Initiative for Asthma (GINA, 2019) recommendations;
- •Patients receiving stable ICS doses with or without long-acting β2-agonists;
- •Еosinophil blood level measured twice at a 1 week interval, of ≥ 300 cells/µl ;
- •Signs of partially controlled BA within 4 weeks prior to screening according to GINA 2019 recommendations;
- •FEV1 value prior to the use of bronchodilators in the range of 55 to 85% of the proper value (inclusive);
- •Consent of patients to use adequate contraception methods throughout the study;
- •Ability to comply with all the study protocol requirements.
排除标准
- •Pregnant or lactating women, or women planning to get pregnant during the clinical study; women of child-bearing potential (including those without history of surgical sterilization and women with <2 years post-menopause) not using adequate contraception methods;
- •Smoking for 1 year prior to screening or previous smoking history of more than 10 packs/year;
- •Severe exacerbations or uncontrolled BA within 3 months prior to screening;
- •Chronic obstructive pulmonary disease (COPD) or other serious lung diseases other than asthma;
- •Inflammatory diseases of the oral cavity at screening;
- •An acute infectious disease within 30 days prior to screening;
- •Participation in any clinical study or any study drug administration within 30 days prior to screening;
- •Taking or indications for taking of prohibited drugs (including anti-leukotriene preparations, modified-release theophylline, etc.);
- •Indications for long-term use of systemic steroids or nonsteroidal anti-inflammatory drugs or drugs affecting on the immune system;
- •The need for periodical intake of antihistamines during the study (stable doses of antihistamines for at least 1 month prior to screening and throughout the study is allowed);
- •Immunosuppressant therapy within 3 months prior to screening;
- •Anaphylaxis, generalized urticaria, or angioedema within 1 year prior to screening;
- •Known allergies, hypersensitivity or contraindications for XC8 or its ingredients;
- •A history of systemic autoimmune diseases or vascular collagenosis;
- •Malignancies within the last 5 years (except for the cured basal cell carcinoma);
- •Significant cardiovascular diseases diagnosed at present or within 12 months prior to screening; uncontrolled hypertension with systolic blood pressure > 180 mm Hg and diastolic blood pressure > 110 mm Hg; pulmonary embolism or deep vein thrombosis;
- •Nephrotic syndrome, moderate to severe chronic renal failure or significant renal impairment with creatinine level >1.5 mg/dL (132 μM/l) in males and > 1.4 mg/dL (123 μM/l) in females or glomerular filtration rate < 60 mL/min;
- •HIV, hepatitis B or C, history of cirrhosis; 3-fold increased serum aspartate aminotransferase or alanine aminotransferase > above the Upper Limit of Normal; 2-fold increased total bilirubin level > above at screening;
- •Anemia (hemoglobin level ≤ 10.5 g/dL in females or ≤ 11.5 g/dL in males); significant blood loss or collection of at least one volumetric unit of donated blood (> 500 mL), or blood transfusion within 12 weeks prior to screening;
- •Any concomitant disease, other than asthma, not controlled by a stable therapy regimen;
- •Drugs or alcohol abuse at screening or in the past, which, in the Investigator's opinion, makes the patient not eligible for participation in the study;
- •Inability to read or write; unwillingness to understand and comply with the protocol procedures; non-compliance with the drug dosing regimen or procedures which, in the Investigator's opinion, may affect study results or the patient's safety and prevent the patient's participation in the study; any other concomitant diseases or severe mental disorders, which make the patient ineligible for participation in the study, limit the legal basis for Informed Consent procedure, or may affect the patient's ability to participate in the study.
研究组 & 干预措施
XC8 100 mg
XC8 100 mg orally
干预措施: XC8 100 mg (Drug)
Placebo
Placebo orally
干预措施: Placebo (Drug)
结局指标
主要结局
Rate of achieving the minimal clinically significant absolute change in FEV1 (+200 mL)
时间窗: Week 0 - Week 12
To assess the rate of achieving minimal clinically significant absolute change in FEV1 measured in mL compared to baseline through spirometry testing.
次要结局
- Changes in FEV1 (in mL)(Week 0 - Week 12)
- Rate of exacerbations of BA(Week 0 - Week 12)
- Change in the Asthma Control Questionnaire 7 (ACQ-7) scores(Week 0 - Week 12)
- Number of Adverse Events (AEs) and Serious Adverse Events (SAEs)(Week 0 - Week 14)
- Change in FEV1/FVC (in % of predicted)(Week 0 - Week 12)
- Change in forced expiratory flow (FEF) 25-75% (in % of predicted)(Week 0 - Week 12)
- Changes in FEV1 (in % of predicted)(Week 0 - Week 12)
- Change in forced vital capacity of lungs (FVC) in % of predicted(Week 0 - Week 12)
- Change in Peak Expiratory Flow (PEF) Rate(Week 0 - Week 12)